SONM stock news
This page provides real-time market news, earnings updates, and company announcements related to DNA X, Inc. (SONM).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-13 01:52 EST
Life Sciences Tools & Services Stocks Fourth Quarter Overview: Comparing PacBio (NASDAQ:PACB)
101 finance2026-03-04 12:15:14
Mapping the S-Curve: INOVIO's Partnership in GBM as a Strategic Move Toward Advancing DNA Immunotherapy Platforms
101 finance2026-03-04 13:30:53
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
Finviz2026-03-04 13:03:48
Vishay Intertechnology RGB LED in 0404 Package Provides Independent Control of Red, True Green, and Blue Chips for Wide Color Range
Finviz2026-03-04 16:03:02
BillionToOne: Overview of Fourth Quarter Financial Results
101 finance2026-03-04 21:48:14
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Finviz2026-03-04 22:03:44
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:22:06
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:25:25
Life Sciences Tools & Services Stocks Q4 Overview: Comparing 10x Genomics (NASDAQ:TXG) With Its Competitors
101 finance2026-03-06 22:57:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Finviz2026-03-09 11:03:47
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Korro Announces Oversubscribed $85 Million Private Placement
Finviz2026-03-09 11:33:52
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Finviz2026-03-09 12:48:57
Should You Consider Purchasing, Retaining, or Selling Tempus AI Shares as 2026 Approaches?
101 finance2026-03-09 14:04:53
3 Lucrative Stocks with Unresolved Issues
101 finance2026-03-09 16:06:13
3 Lucrative Stocks That Still Raise Some Questions
101 finance2026-03-09 16:06:13
Networking now 30% of HPE revenue but over half of profits
Finviz2026-03-10 17:04:05
Rivian’s R2 Debut in the First Half of 2026 May Be the Key Test That Validates or Challenges Its Volume Advantage
101 finance2026-03-10 17:40:18
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
Finviz2026-03-11 20:09:56
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Finviz2026-03-12 12:09:10
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Finviz2026-03-12 12:36:55
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:09:50
BillionToOne: Overview of Fourth Quarter Financial Results
101 finance2026-03-04 21:48:14
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Finviz2026-03-04 22:03:44
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Finviz2026-03-06 12:46:17
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:22:06
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC
Finviz2026-03-06 15:25:25
Life Sciences Tools & Services Stocks Q4 Overview: Comparing 10x Genomics (NASDAQ:TXG) With Its Competitors
101 finance2026-03-06 22:57:39
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Finviz2026-03-09 11:03:47
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Finviz2026-03-09 11:03:49
Korro Announces Oversubscribed $85 Million Private Placement
Finviz2026-03-09 11:33:52
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Finviz2026-03-09 12:48:57
Should You Consider Purchasing, Retaining, or Selling Tempus AI Shares as 2026 Approaches?
101 finance2026-03-09 14:04:53
3 Lucrative Stocks with Unresolved Issues
101 finance2026-03-09 16:06:13
3 Lucrative Stocks That Still Raise Some Questions
101 finance2026-03-09 16:06:13
Networking now 30% of HPE revenue but over half of profits
Finviz2026-03-10 17:04:05
Rivian’s R2 Debut in the First Half of 2026 May Be the Key Test That Validates or Challenges Its Volume Advantage
101 finance2026-03-10 17:40:18
Waldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings Date
Finviz2026-03-11 20:09:56
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Finviz2026-03-12 12:09:10
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Finviz2026-03-12 12:36:55
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-12 20:09:50
SONM stock chart
SONM stock detailsSONM stock price change
On the last trading day, SONM stock closed at 3.88 USD, with a price change of -9.35% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more